Sanofi (SNY) Current Assets (2009 - 2026)
Sanofi (SNY) posted Current Assets of $36.6 billion for Q2 2026, up 3.75% sequentially from $35.3 billion in Q1 2026, and down 12.56% YoY from $41.9 billion in Q2 2025.
Sanofi (SNY) Current Assets (2009 - 2026) Analysis & Trends
Sanofi has reported Current Assets for 18 years, with the latest figure at $36.6 billion in Q2 2026.
- Quarterly Current Assets fell 12.56% year-over-year to $36.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $36.6 billion (down 12.56% YoY) and the FY2025 annual result came in at $36.0 billion, down 20.83% from the prior year.
- Current Assets improved to $36.6 billion in Q2 2026 per SNY's latest filing, from $35.3 billion in the prior quarter.
- Over five years, Current Assets peaked at $46.3 billion in Q1 2025 and troughed at $30.3 billion in Q2 2022.
- A 5-year average of $37.0 billion and a median of $35.7 billion in 2025 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2026: Current Assets jumped 37.91% in 2024, then retreated 23.73% in 2026.
- Over 5 years, Current Assets stood at $34.8 billion in 2022, then slipped by 5.18% to $33.0 billion in 2023, then soared by 37.91% to $45.5 billion in 2024, then fell by 20.83% to $36.0 billion in 2025, then rose by 1.69% to $36.6 billion in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $36.6 billion, $35.3 billion, and $36.0 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 59.77 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 33.67 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 36.68 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 27.35 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 27.97 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 34.96 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 13.95 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 41.36 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 23.56 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 36.64 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.64 Bn |
| Mar 31, 2026 | 35.31 Bn |
| Dec 31, 2025 | 36.03 Bn |
| Sep 30, 2025 | 39.80 Bn |
| Jun 30, 2025 | 41.90 Bn |
| Mar 31, 2025 | 46.30 Bn |
| Dec 31, 2024 | 45.51 Bn |
| Jun 30, 2024 | 32.39 Bn |
| Dec 31, 2023 | 33.00 Bn |
| Jun 30, 2023 | 32.64 Bn |
| Dec 31, 2022 | 34.80 Bn |
| Jun 30, 2022 | 30.26 Bn |
| Dec 31, 2021 | 34.96 Bn |
| Jun 30, 2021 | 35.53 Bn |
| Dec 31, 2020 | 40.18 Bn |
| Jun 30, 2020 | 38.32 Bn |
| Dec 31, 2019 | 1.08 Bn |
| Jun 30, 2019 | 28.44 Bn |
| Dec 31, 2018 | 28.05 Bn |
| Jun 30, 2018 | 28.57 Bn |